A Prospective, Multicenter, Single-arm Study to Evaluate the Safety and Tolerability of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Treprostinil (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors United Therapeutics Corporation
- 07 Apr 2017 Planned initiation date changed from 1 Mar 2017 to 1 Apr 2017.
- 07 Apr 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 10 Jan 2017 New trial record